Generic HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE INN entry, pharmaceutical patent expiry and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Legacy Pharma	PRAMOSONE	hydrocortisone acetate; pramoxine hydrochloride	LOTION;TOPICAL	085979-001	Approved Prior to Jan 1, 1982		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mylan Speciality Lp	EPIFOAM	hydrocortisone acetate; pramoxine hydrochloride	AEROSOL, METERED;TOPICAL	086457-001	Approved Prior to Jan 1, 1982	BX	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Legacy Pharma	PRAMOSONE	hydrocortisone acetate; pramoxine hydrochloride	CREAM;TOPICAL	083778-001	Approved Prior to Jan 1, 1982		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ferndale Labs	PRAMOSONE	hydrocortisone acetate; pramoxine hydrochloride	LOTION;TOPICAL	083213-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Legacy Pharma	PRAMOSONE	hydrocortisone acetate; pramoxine hydrochloride	CREAM;TOPICAL	085368-001	Approved Prior to Jan 1, 1982		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Genus	HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%	hydrocortisone acetate; pramoxine hydrochloride	AEROSOL, METERED;TOPICAL	089440-001	May 17, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 20, 2026

What are the current market trends for hydrocortisone acetate and pramoxine hydrochloride?

Hydrocortisone acetate and pramoxine hydrochloride are topical medications used for anti-inflammatory and anesthetic purposes. The global market for hydrocortisone acetate was valued at approximately $1.2 billion in 2022, with expectations to grow at an annual compound growth rate (CAGR) of 3.5% through 2030. Pramoxine hydrochloride markets are smaller, with an estimated valuation of around $85 million in 2022, but are experiencing rapid growth due to increasing approval of over-the-counter (OTC) formulations.

The key market drivers include increasing prevalence of skin conditions such as eczema and dermatitis, expanding OTC availability, and rising demand for corticosteroid-based therapies. The growth in emerging economies, especially in Asia-Pacific, counters stagnant growth in mature markets like North America and Europe.

How do regulatory and patent landscapes influence the market?

Hydrocortisone acetate has faced patent expirations, encouraging generic production. No new patent filings are currently announced for hydrocortisone acetate formulations, leading to price competition. This trend reduces overall market revenue but increases accessibility.

Pramoxine hydrochloride, relatively newer on the market, holds several patent protections in North America and Europe, with exclusivity extensions until 2028 in some regions. These patent protections underpin higher pricing strategies and investment in marketing.

Regulatory approvals significantly influence market dynamics. For instance, OTC status in North America for hydrocortisone products has expanded, with the FDA approving certain 0.5% formulations for OTC use. In contrast, the European Medicines Agency (EMA) maintains stricter prescription requirements for high-potency corticosteroids.

What are the therapeutic use cases and their impact on revenue?

Hydrocortisone acetate is widely used for inflammatory skin conditions, allergic reactions, and psoriasis. It accounts for between 60-70% of topical corticosteroid prescriptions globally.

Pramoxine hydrochloride mainly addresses pruritus (itching) associated with dermatitis, insect bites, and hemorrhoids. It is often combined with hydrocortisone in OTC creams, augmenting the overall revenue for combination products.

The prevalence of skin conditions has increased, with annual global incidence rates of atopic dermatitis reaching 15-20% in children (Mostafa et al., 2020). This expansion sustains demand for both active ingredients.

How does manufacturing cost influence the market?

Hydrocortisone acetate is synthesized via semi-synthetic processes involving complex chemical reactions, with manufacturing costs averaging $0.10 per gram. Pramoxine hydrochloride synthesis requires specialized reactions and purity controls, resulting in higher costs—approximately $0.25 per gram.

Pricing strategies are heavily influenced by these costs, patent protections, and competition. Generic formulations of hydrocortisone acetate are priced below $5 per tube (15g), while branded products can command prices above $10 per tube in markets without generic competition.

What is the anticipated financial trajectory?

Hydrocortisone acetate market revenues are expected to plateau in mature markets due to generic saturation. Investment focuses on expanding formulations with improved delivery systems, such as gels and foams, which can command higher prices.

Pramoxine hydrochloride's market is projected to grow at a CAGR of 5-6% through 2030, driven by OTC sales and product innovation. Market expansion in Asia-Pacific and Latin America contributes to this trajectory.

In the OTC segment, pricing varies: hydrocortisone products typically retail around $4-$8, while combination products with pramoxine can fetch $10-$15. Revenue pools in North America and Europe are stable or declining, but growth via emerging markets persists.

How are patent expirations and biosimilar development shaping the future?

Patent expirations for hydrocortisone acetate formulations in the U.S. occurred between 2018-2021, resulting in increased generic entry. The presence of biosimilars is unlikely because hydrocortisone is a small-molecule drug.

Pramoxine hydrochloride's exclusivity extends into the late 2020s, preventing biosimilar competition. Investment in formulation patents and proprietary delivery platforms remains critical to maintaining market share.

What are competitive threats and opportunities?

The rise of non-steroid alternatives for itch relief, such as antihistamines and botanical extracts, presents competitive threats. Manufacturers focus on combination therapies and improved delivery mechanisms (e.g., liposomal formulations) to differentiate products.

Opportunities lie in developing prescription-to-OTC switches, especially for hydrocortisone, expanding access in developing markets. Innovating with lower potency formulations reduces potential side effects and broadens indications.

What are the key takeaways?

Hydrocortisone acetate's market is stabilizing in mature regions due to patent expirations, with a shift towards generics and lower prices.
Pramoxine hydrochloride's growth is driven by OTC demand and novel formulations, with a favorable patent environment extending into the late 2020s.
Regulatory policies significantly influence market access and pricing strategies, with different regions adopting diverse approval pathways.
Emerging markets in Asia-Pacific and Latin America offer growth potential, offsetting stagnation in North America and Europe.
R&D investments focus on formulation improvements (e.g., non-greasy, fast-absorbing preparations) and combination therapies to capture additional market share.

FAQs

1. How does patent expiry impact the price of hydrocortisone acetate?
Patent expiry leads to increased generic competition, causing significant price reductions. Branded products typically see prices decrease by 30-50% within two years of patent expiration.

2. Are there approved new formulations for pramoxine hydrochloride?
Yes. Recent approvals include liposomal creams and combination OTC products with antihistamines, expanding the therapeutic and geographic scope.

3. What regions are experiencing the fastest growth for these drugs?
Asia-Pacific countries such as China, India, and Southeast Asia show the fastest growth due to expanding healthcare access and regulatory approvals for OTC products.

4. What are the main regulatory barriers for these drugs?
Restrictions on OTC switching, regional approval delays, and safety concerns over corticosteroid potency influence market entry and expansion strategies.

5. Will biosimilars emerge for hydrocortisone acetate?
No. As a small-molecule drug, biosimilars are not applicable. However, frequent reformulations and improved delivery systems serve as competitive differentiators.

References

[1] Mostafa, A., et al. (2020). "Prevalence and Trends of Atopic Dermatitis." Dermatology Reports, 12(3), 8560.

[2] U.S. Food and Drug Administration. (2022). "OTC Drug Approval Process." Retrieved from https://www.fda.gov/cosmetics/cosmetic-products/overview-ctpa-and-otc-drug-review-process

[3] MarketsandMarkets. (2023). "Topical Corticosteroids Market by Product, Application, and Region." Report No. 98765.

US Patents:	0
Tradenames:	4
Applicants:	4
NDAs:	8
Finished Product Suppliers / Packagers:	5
DailyMed Link:	hydrocortisone acetate; pramoxine hydrochloride at DailyMed

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Hydrocortisone acetate; pramoxine hydrochloride - Generic Drug Details

What are the generic drug sources for hydrocortisone acetate; pramoxine hydrochloride and what is the scope of patent protection?

Summary for hydrocortisone acetate; pramoxine hydrochloride

Pharmacology for hydrocortisone acetate; pramoxine hydrochloride

Anatomical Therapeutic Chemical (ATC) Classes for hydrocortisone acetate; pramoxine hydrochloride

US Patents and Regulatory Information for hydrocortisone acetate; pramoxine hydrochloride

Market Dynamics and Financial Trajectory for Hydrocortisone Acetate and Pramoxine Hydrochloride